ClinicalTrials.gg
RecruitingNCT07058662Updated Nov 13, 2026

A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.

A Phase 1/2 interventional study of Single dose intravenous of BBM-D101 in DMD, sponsored by Belief BioMed (Beijing) Co., Ltd. Recruiting at 1 site in China. Open to male participants aged 4 Years to 9 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Belief BioMed (Beijing) Co., Ltd · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Nov 13, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
4 Years to 9 Years
Sex
Male
01

Study summary

The purpose of the study is to evaluate the safety, tolerability, and efficacy of BBM-D101 to treat participants with Duchenne Muscular Dystrophy.

Read the detailed description

This is a single-arm, open-label study to evaluate the safety, tolerability, efficacy, pharmacokinetic, pharmacodynamic, and immune response of BBM-D101 within 52 weeks after a single intravenous infusion in DMD boys, as well as the long-term safety and efficacy of BBM-D101 for up to 5 years post infusion.

BBM-D101 is a gene addition therapy based on engineered AAV delivery therapeutic protein gene cassette into muscle for treating DMD. Therapeutic protein could mediate the dystrophin-associated protein complex to prevent muscular dystrophy and to rescue the function of muscle.

02

Conditions studied

  • DMD

Keywords

  • DMD
  • gene therapy
  • Adeno-Associated Virus
03

In context

Lead sponsor

Belief BioMed (Beijing) Co., Ltd is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 9 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The Participants and/or his legal guardian must fully understand the purpose, nature, methods, and potential risks of the study, and sign a written form.
  2. Ambulatory male subjects aged 4 years and above but under 9 years (4 years ≤ age \< 9 years).
  3. Any mutation in the DMD gene confirmed by genetic testing
  4. Serum creatine kinase (CK) during the screening period meets the study requirements.
  5. Receiving stable, standard-dose before screening.
  6. The subject's AAV capsid antibodies meet the clinical trial requirements.
  7. Able to cooperate with motor function assessment, MRI, and muscle as required by the study.
  8. Laboratory test results during the screening period and at baseline meet the standards.
  9. The subject and/or his legal guardian must fully understand the study procedures, be willing to actively cooperate, commit to high compliance with the protocol, and ensure that the subject attends all scheduled visits.

Exclusion criteria

Exclusion Criteria:

  1. Positive for surface antigen (HBsAg), hepatitis B virus deoxyribonucleic acid (HBV-DNA) ≥ 1000 U/mL, virus ribonucleic acid (HCV-RNA) positive, (HIV) positive, or positive for Treponema pallidum antibodies.
  2. Currently receiving antiviral therapy for hepatitis B, hepatitis C, HIV, etc.
  3. The investigator deems the subject has severe behavioral or cognitive disorders that may hinder participation in this study.
  4. Poorly controlled asthma, or Duchenne Muscular Dystrophy (DMD) leading to significant decline in lung function, or recurrent infectious pneumonia that the investigator considers may affect respiratory function.
  5. (LVEF) \< 50% or (NYHA) cardiac function class ≥ III.
  6. Severe or persistent arrhythmias (such as atrial fibrillation, frequent ventricular premature beats, ventricular bigeminy, ventricular trigeminy, severe bundle branch block, etc.), and congenital heart disease that is evaluated by the investigator as unsuitable for participation in this study.
  7. Any changes in preventive/cardiomyopathy treatment (initiation of treatment, drug changes, dosing regimen changes, treatment interruption, termination, or restart) within 1 month before the infusion of the study drug.
  8. History of liver diseases such as portal hypertension, splenomegaly, hepatic encephalopathy, liver fibrosis ≥ stage 3, or hepatic nodules/cysts found by ultrasound during screening, or elevated alpha-fetoprotein with clinical significance as determined by the investigator.
  9. Severe infection (such as pneumonia, pyelonephritis, or meningitis) within 4 weeks before the treatment visit (enrollment may be postponed).
  10. History of gene therapy or cell therapy (such as stem cell transplantation).
  11. History of or current presence of diseases, severe renal, gastrointestinal, neurological, or coagulation disorders, malignant tumors, or other diseases.
  12. Other diseases that the investigator deems unsuitable for participation in this study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    Arm of BBM-D101

    Single-dose treatment

    Genetic: Single dose intravenous of BBM-D101

Interventions

  • GeneticSingle dose intravenous of BBM-D101

    BBM-D101 is a gene addition therapy based on engineered AAV delivery therapeutic protein gene cassette into muscle for treating DMD. Therapeutic protein could mediate the dystrophin-associated protein complex to prevent muscular dystrophy and to rescue the function of muscle.The administration is completed by a single intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicity (DLT) events

    To evaluate the rate of incidence of DLT events determined by the Safety Data Review Committee (SRC) in DLT observation period after BBM-D101 infusion.

    Time frame: Within 12 weeks

  2. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    To evaluate the safety of BBM-D101 by AEs and SAEs.

    Time frame: Within 12 weeks

Secondary outcomes

  1. Changes from baseline in BBM-D101 therapeutic protein level of muscle biopsy samples

    To assess changes of therapatic protein from baseline in muscle after BBM-D101 Infusion.

    Time frame: Within 52 weeks

  2. Changes from baseline in serum Creatine Kinase (CK) level

    To assess changes of serum CK after BBM-D101 Infusion.

    Time frame: Within 52 weeks

  3. Changes from baseline in the time to ascend time to rise (TTR) without assistance

    To assess changes in TTR from baseline within 52 weeks after BBM-D101 infusion.

    Time frame: Within 52 weeks

  4. Changes from baseline in the time to ascend 10-meter walk/run test (10MWR) without assistance

    To assess changes in 10MWR from baseline within 52 weeks after BBM-D101 infusion.

    Time frame: Within 52 weeks

  5. Changes from baseline in the time to ascend 4 steps (4-stair climb, 4-SC) without assistance.

    To assess changes in 4-SC from baseline within 52 weeks after BBM-D101 infusion.

    Time frame: Within 52 weeks

  6. Changes from baseline in the North Star Ambulatory Assessment (NSAA).

    To assess changes in NSAA from baseline within 52 weeks after BBM-D101 infusion; The NSAA is a scale that rates performance of various motor abilities in ambulant children with Duchenne Muscular Dystrophy and is used to monitor disease progression and treatment effects. The NSAA total score is defined as the sum of all 17items, ranging from 0 (worst) to 34 (best).

    Time frame: Within 52 weeks

  7. Changes from baseline in the TTR, 10MWR , 4-SC,NSAA.

    Evaluate the changes from baseline in TTR, 10MWR, 4-SC and NSAA in Participants after Infusion of BBM-D101.

    Time frame: Within 5 years

  8. Incidence of AEs and SAEs.

    To assess the long-term safety of BBM-D101 by AEs and SAEs.

    Time frame: Within 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jun 2027, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2025
First posted
Jul 10, 2025
StartActual
Jul 31, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2031
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: h•••@beliefbiomed.com · •••8288→j•••@beliefbiomed.com · •••8288. See the current contact
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Contact Study contact changed: h•••@beliefbiomed.com · •••8288→j•••@beliefbiomed.com · •••8288. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07058662
Lead sponsor
Belief BioMed (Beijing) Co., Ltd
Collaborators
Shanghai Mianyi Biopharmaceutical Co., Ltd., Shanghai Xinzhi BioMed Co., Ltd., Belief BioMed Limited
Responsible party
Sponsor
First posted
Jul 10, 2025
Start date
Jul 31, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2031 (estimated)
Last update
Nov 13, 2026

Study contacts

Wei Jiang, Ph.D
Contact
jwei@beliefbiomed.com
+86-021-33588288
DMD Clinical Trial Team
Contact
DMDclinicaltrial@beliefbiomed.com
Yi Dai, MD
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion